South Korea · Delayed Price · Currency is KRW BioInfra Statistics
Total Valuation
BioInfra has a market cap or net worth of KRW 7.06 billion. The enterprise value is 13.76 billion.
| Market Cap | 7.06B |
| Enterprise Value | 13.76B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
BioInfra has 4.86 million shares outstanding. The number of shares has decreased by -0.05% in one year.
| Current Share Class | 4.86M |
| Shares Outstanding | 4.86M |
| Shares Change (YoY) | -0.05% |
| Shares Change (QoQ) | +3.70% |
| Owned by Insiders (%) | 51.44% |
| Owned by Institutions (%) | n/a |
| Float | 2.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.28 |
| PB Ratio | 0.56 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.58, with a Debt / Equity ratio of 1.09.
| Current Ratio | 0.58 |
| Quick Ratio | 0.49 |
| Debt / Equity | 1.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.49 |
| Interest Coverage | -13.09 |
Financial Efficiency
Return on equity (ROE) is -47.52% and return on invested capital (ROIC) is -29.17%.
| Return on Equity (ROE) | -47.52% |
| Return on Assets (ROA) | -9.12% |
| Return on Invested Capital (ROIC) | -29.17% |
| Return on Capital Employed (ROCE) | -39.84% |
| Weighted Average Cost of Capital (WACC) | 3.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.71 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BioInfra has paid 1.05 billion in taxes.
| Income Tax | 1.05B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.70% in the last 52 weeks. The beta is 0.42, so BioInfra's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -71.70% |
| 50-Day Moving Average | 1,852.66 |
| 200-Day Moving Average | 3,613.52 |
| Relative Strength Index (RSI) | 41.08 |
| Average Volume (20 Days) | 53,326 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioInfra had revenue of KRW 25.62 billion and -8.29 billion in losses. Loss per share was -1,704.38.
| Revenue | 25.62B |
| Gross Profit | 6.45B |
| Operating Income | -5.29B |
| Pretax Income | -7.23B |
| Net Income | -8.29B |
| EBITDA | -1.74B |
| EBIT | -5.29B |
| Loss Per Share | -1,704.38 |
Balance Sheet
The company has 7.04 billion in cash and 13.74 billion in debt, with a net cash position of -6.70 billion or -1,377.69 per share.
| Cash & Cash Equivalents | 7.04B |
| Total Debt | 13.74B |
| Net Cash | -6.70B |
| Net Cash Per Share | -1,377.69 |
| Equity (Book Value) | 12.60B |
| Book Value Per Share | 2,497.20 |
| Working Capital | -8.77B |
Cash Flow
In the last 12 months, operating cash flow was -1.35 billion and capital expenditures -1.15 billion, giving a free cash flow of -2.50 billion.
| Operating Cash Flow | -1.35B |
| Capital Expenditures | -1.15B |
| Depreciation & Amortization | 3.54B |
| Net Borrowing | 1.52B |
| Free Cash Flow | -2.50B |
| FCF Per Share | -514.70 |
Margins
Gross margin is 25.18%, with operating and profit margins of -20.63% and -32.34%.
| Gross Margin | 25.18% |
| Operating Margin | -20.63% |
| Pretax Margin | -28.23% |
| Profit Margin | -32.34% |
| EBITDA Margin | -6.81% |
| EBIT Margin | -20.63% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 300.00, which amounts to a dividend yield of 19.72%.
| Dividend Per Share | 300.00 |
| Dividend Yield | 19.72% |
| Dividend Growth (YoY) | -25.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.05% |
| Shareholder Yield | 19.77% |
| Earnings Yield | -117.33% |
| FCF Yield | -35.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioInfra has an Altman Z-Score of 0.65 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.65 |
| Piotroski F-Score | 3 |